Johnson & Johnson seeks nipocalimab approval for broadest antibody positive myasthenia gravis population

Johnson & Johnson has taken a significant step by submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of nipocalimab. This investigational treatment is aimed at patients suffering from generalized myasthenia gravis (gMG). The application marks the first instance of seeking global approval for nipocalimab, a monoclonal antibody specifically designed to bind with high affinity and specificity to neonatal Fc receptor (FcRn) and lower autoantibody levels. 

The BLA submission is backed by data from the Phase 3 Vivacity-MG3 study, which showcased notable outcomes for patients who were administered nipocalimab along with standard care compared to those who received a placebo and standard care. The primary measurement focused on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline over a 24-week period. The study involved antibody-positive adult patients, specifically those positive for anti-acetylcholine receptor (anti-AChR+), anti-muscle-specific tyrosine kinase (anti-MuSK+), and anti-low-density lipoprotein receptor-related protein 4 (anti-LRP4+). These subtypes cover about 95% of the gMG patient demographic, making this study the first to show controlled disease management in these specific subtypes. Safety and tolerability results were consistent with previous nipocalimab trials.

Bill Martin, Ph.D., Global Therapeutic Area Head of Neuroscience at Johnson & Johnson, expressed optimism about nipocalimab's potential to offer sustained disease control for individuals affected by generalized myasthenia gravis. He highlighted that the filing for FDA approval is a crucial milestone for the company, which continues to innovate in the realm of autoantibody-driven diseases. Johnson & Johnson aims to collaborate closely with the FDA during the review process.

Nipocalimab stands out as the first and only FcRn blocker to show sustained disease control over six months of consistent dosing. This long-term safety and efficacy assessment sets it apart in the class of FcRn blockers. Earlier this year, Johnson & Johnson presented data at the American Academy of Neurology Annual Meeting, underlining nipocalimab’s molecular properties, including its high binding affinity and specificity to the FcRn IgG binding site. These attributes are thought to significantly impact IgG autoantibody levels in diseases such as gMG and other similar conditions.

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder where the body's immune system mistakenly attacks proteins at the neuromuscular junction, impairing muscle function. The disease affects approximately 700,000 people globally and has a higher prevalence among young women and older men. Symptoms can include muscle weakness, drooping eyelids, double vision, and difficulties in chewing, swallowing, speech, and breathing.

The Phase 3 Vivacity-MG3 study was meticulously designed to evaluate both sustained efficacy and safety in this unpredictable disease. The trial involved 199 patients, including 153 antibody-positive individuals, who were either assigned to receive nipocalimab plus standard care or a placebo plus standard care. The primary endpoint was the change in the MG-ADL score from baseline over weeks 22, 23, and 24.

Nipocalimab is an investigational monoclonal antibody developed to bind with high affinity to FcRn and reduce circulating immunoglobulin G (IgG) antibodies, thereby preserving immune function without broad immunosuppression. Its potential applications extend across various conditions involving autoantibodies and alloantibodies.

The U.S. FDA and the European Medicines Agency (EMA) have recognized nipocalimab with several key designations, including Fast Track, Orphan Drug, and Breakthrough Therapy status for various conditions, underscoring its potential as a significant therapeutic advancement.

Johnson & Johnson remains committed to leveraging its expertise in healthcare innovation to address complex diseases and deliver impactful treatments, with nipocalimab representing a promising step forward in the management of generalized myasthenia gravis and potentially other autoantibody-driven diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!